Last reviewed · How we verify
TNF antagonist
TNF antagonist is a TNF antagonist Small molecule drug developed by Brigham and Women's Hospital. It is currently FDA-approved for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.
TNF antagonists block tumor necrosis factor (TNF), a key inflammatory cytokine that drives immune-mediated inflammation.
TNF antagonists, such as Adalimumab, are used to treat conditions including Crohn's Disease, Polyarticular Course Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, and Reactive Arthritis. They work by suppressing the inflammatory response caused by tumor necrosis factor (TNF), a key component of the body's inflammatory response.
At a glance
| Generic name | TNF antagonist |
|---|---|
| Sponsor | Brigham and Women's Hospital |
| Drug class | TNF antagonist |
| Target | TNF-α (Tumor Necrosis Factor-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
TNF antagonists inhibit TNF-α signaling by either binding directly to TNF-α (monoclonal antibodies) or acting as TNF receptors that sequester TNF (fusion proteins). This reduces the activation of immune cells and inflammatory cascades, thereby suppressing pathological inflammation in autoimmune and inflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriasis
- Psoriatic arthritis
Common side effects
- Increased infection risk (including tuberculosis)
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Demyelinating disease (rare)
Key clinical trials
- Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients (PHASE2)
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Association of Erectile Dysfunction With Neuropathic Pain, Disease Activity, and Functional Status in Male Patients With Axial Spondyloarthritis: A Cross-Sectional Observational Study
- Lumbar Spinal Fibrosis and TNF Alpha Inhibition (PHASE3)
- Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
- A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNF antagonist CI brief — competitive landscape report
- TNF antagonist updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI
Frequently asked questions about TNF antagonist
What is TNF antagonist?
How does TNF antagonist work?
What is TNF antagonist used for?
Who makes TNF antagonist?
What drug class is TNF antagonist in?
What development phase is TNF antagonist in?
What are the side effects of TNF antagonist?
What does TNF antagonist target?
Related
- Drug class: All TNF antagonist drugs
- Target: All drugs targeting TNF-α (Tumor Necrosis Factor-alpha)
- Manufacturer: Brigham and Women's Hospital — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Crohn's disease
- Indication: Drugs for Ulcerative colitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing